Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Alterations in lipoprotein metabolism enhance the risk of cardiometabolic disorders including type-2 diabetes and atherosclerosis, the leading cause of death in Western societies. While the transcriptional regulation of lipid metabolism has been well characterized, recent studies have uncovered the importance of microRNAs (miRNAs), long-non-coding RNAs (lncRNAs) and RNA binding proteins (RBP) in regulating the expression of lipid-related genes at the posttranscriptional level. Work from several groups has identified a number of miRNAs, including miR-33, miR-122 and miR-148a, that play a prominent role in controlling cholesterol homeostasis and lipoprotein metabolism. Importantly, dysregulation of miRNA expression has been associated with dyslipidemia, suggesting that manipulating the expression of these miRNAs could be a useful therapeutic approach to ameliorate cardiovascular disease (CVD). The role of lncRNAs in regulating lipid metabolism has recently emerged and several groups have demonstrated their regulation of lipoprotein metabolism. However, given the high abundance of lncRNAs and the poor-genetic conservation between species, much work will be needed to elucidate the specific role of lncRNAs in controlling lipoprotein metabolism. In this review article, we summarize recent findings in the field and highlight the specific contribution of lncRNAs and RBPs in regulating lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082 · cited 3×
“It is thought that the reduced circulating cholesterol observed in mice treated with miR-122 antagonists is due to alterations in a combination of different metabolic processes, including the inhibition of cholesterol and fatty acid biosynthesis, enhanced fatty acid oxidation and decreased VLDL secretion [26, 81, 82].”
BackgroundLong noncoding RNAs: past, present, and future
Kung, J. T. Y., Colognori, D., & Lee, J. T. (2013) · Genetics · doi:10.1534/genetics.112.146704 · Cited by 1,874
The biogenesis and emerging roles of circular RNAs
Chen, L.-L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.32 · Cited by 1,743
Price, N. L., Gomes, A. P., Ling, A. J. Y., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.003 · Cited by 1,602 · cited 4×
“As research into miR-33 as a potential therapeutic target for the treatment of CVD continues to grow, recent reports suggest that miR-33 may also influence cholesterol efflux through additional mechanisms independent of its regulation of ABCA1 and ABCG1 expression. miR-33 has been shown to target AMPK, a nutrient sens…”
BackgroundSelf-citationThe gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
RNA regulons: coordination of post-transcriptional events
Keene, J. D. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2111 · Cited by 1,321 · cited 2×
“In addition to lncRNAs, RNA binding proteins (RBPs) are known to regulate all aspects of mRNA metabolism including processing, transport, translation, and turnover via different RNA interaction motifs generally present in the 3′UTR of the target mRNA [16].”
BackgroundMiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
Self-citationMicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M. (2010) · Science · doi:10.1126/science.1189123 · Cited by 957
Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport
Rosenson, R. S., Brewer, H. B., Davidson, W. S., Fayad, Z. A., Fuster, V., Goldstein, J., Hellerstein, M., Jiang, X.-C., Phillips, M. C., Rader, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.066589 · Cited by 953 · cited 1×
“Reverse cholesterol transport (RCT) is an important biological process to reduce excess cholesterol and transport from the peripheral tissues to the liver, where cholesterol can be reutilized or excreted into feces [51, 52].”
BackgroundHDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870 · cited 1×
“Reverse cholesterol transport (RCT) is an important biological process to reduce excess cholesterol and transport from the peripheral tissues to the liver, where cholesterol can be reutilized or excreted into feces [51, 52].”
BackgroundInhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706
Self-citationRayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · cited 2×
“Interestingly, the three reports that found significant reduction in atherosclerotic burden without affecting circulating HDL-C also demonstrated the efficacy of anti-miR-33 therapy in targeting atherosclerotic plaque macrophages and the whole aorta [36, 63, 64, 66, 67].”
BackgroundmiR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling
Dávalos, A., Goedeke, L., Smibert, P., Ramírez, C. M., Warrier, N. P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102281108 · Cited by 670 · cited 1×
“Among the miRNAs involved in regulation of HDL-C metabolism, miR-33 is deemed to be one of the most important, due to its ability to regulate numerous key functions including cholesterol efflux, transport and uptake; HDL biogenesis; bile acid synthesis and secretion; and fatty acid degradation [40, 53-58].”
BackgroundSelf-citationDiverse molecular functions of Hu proteins
Hinman, M. N., & Lou, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8252-6 · Cited by 587 · cited 1×
“Human antigen R (HuR), also known as embryonic lethal, abnormal vision Drosophila-like 1 (ELAVL1), is a ubiquitously expressed RBP belonging to the Hu/Elav family, that modulates the stability and translational efficiency of mRNAs by interacting with uridylate (U)-rich or adenylate-uridylate (AU)-rich elements in the…”
BackgroundmiR-33 links SREBP-2 induction to repression of sterol transporters
Marquart, T. J., Allen, R. M., Ory, D. S., & Baldán, Á. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005191107 · Cited by 562
HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells
Tabet, F., Vickers, K. C., Cuesta Torres, L. F., Wiese, C. B., Shoucri, B. M., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M. G., Thacker, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms4292 · Cited by 428 · cited 1×
“In a follow up study, Tabet and colleagues, demonstrated for the first time that HDL-transfer of miRNAs to endothelial cells (ECs) can regulate EC activation [78].”
BackgroundHoldt, L. M., Hoffmann, S., Sass, K., Langenberger, D., Scholz, M., Krohn, K., Finstermeier, K., Stahringer, A., Wilfert, W., Beutner, F., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003588 · Cited by 397
Ouimet, M., Ediriweera, H. N., Gundra, U. M., Sheedy, F. J., Ramkhelawon, B., Hutchison, S. B., Rinehold, K., van Solingen, C., Fullerton, M. D., Cecchini, K., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81676 · Cited by 394 · cited 1×
“Interestingly, the three reports that found significant reduction in atherosclerotic burden without affecting circulating HDL-C also demonstrated the efficacy of anti-miR-33 therapy in targeting atherosclerotic plaque macrophages and the whole aorta [36, 63, 64, 66, 67].”
BackgroundHorie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384
Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*
Gerin, I., Clerbaux, L.-A., Haumont, O., Lanthier, N., Das, A. K., Burant, C. F., Leclercq, I. A., MacDougald, O. A., & Bommer, G. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152090 · Cited by 382 · cited 1×
“Among the miRNAs involved in regulation of HDL-C metabolism, miR-33 is deemed to be one of the most important, due to its ability to regulate numerous key functions including cholesterol efflux, transport and uptake; HDL biogenesis; bile acid synthesis and secretion; and fatty acid degradation [40, 53-58].”
BackgroundIntracellular cholesterol transport
Soccio, R. E., & Breslow, J. L. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000131264.66417.d5 · Cited by 297 · cited 1×
“Excess intracellular cholesterol represses de novo cholesterol biosynthesis and simultaneously activates acylcoenzyme A: cholesterol acyltransferase (ACAT), an ERlocalized enzyme that converts cholesterol into cholesterol esters for storage along with triglycerides in the cores of cytosolic lipid droplets [45].”
BackgroundMicroRNAs in Metabolic Disease
Fernández-Hernando, C., Ramírez, C. M., Goedeke, L., & Suárez, Y. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300144 · Cited by 257 · cited 1×
“Dysregulation of miRNA expression or genetic variants associated with miRNAs or miRNA binding site loci have been associated with cardiometabolic diseases such as obesity, insulin resistance and atherosclerosis [6, 7].”
BackgroundSelf-citationControl of Cholesterol Metabolism and Plasma High-Density Lipoprotein Levels by microRNA-144
Ramírez, C. M., Rotllan, N., Vlassov, A. V., Dávalos, A., Li, M., Goedeke, L., Aranda, J. F., Cirera-Salinas, D., Araldi, E., Salerno, A., et al. (2013) · Circulation Research · doi:10.1161/circresaha.112.300626 · Cited by 233 · cited 1×
“Inhibition of miR-148a and miR-144 increases hepatic ABCA1 expression and plasma HDL-C levels in mice [32, 34, 70, 71].”
BackgroundSelf-citationMicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice
Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Nakao, T., Nishiga, M., Usami, S., Izuhara, M., Sowa, N., Yahagi, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3883 · Cited by 230 · cited 1×
“In the first report, Horie and colleagues showed that miR-33-/mice develop obesity and metabolic dysfunction and have increased total cholesterol levels, especially in mice on a high fat diet (HFD), while circulating TAGs were not found to be altered [86].”
BackgroundmicroRNA-33 regulates macrophage autophagy in atherosclerosis
Ouimet, M., Ediriweera, H., Afonso, M. S., Ramkhelawon, B., Singaravelu, R., Liao, X., Bandler, R. C., Rahman, K., Fisher, E. A., Rayner, K. J., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308916 · Cited by 221
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220
Karunakaran, D., Thrush, A. B., Nguyen, M.-A., Richards, L., Geoffrion, M., Singaravelu, R., Ramphos, E., Shangari, P., Ouimet, M., Pezacki, J. P., et al. (2015) · Circulation Research · doi:10.1161/circresaha.117.305624 · Cited by 188
Rotllan, N., Ramírez, C. M., Aryal, B., Esau, C. C., & Fernández-Hernando, C. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301732 · Cited by 174
Self-citationAllen, R. M., Marquart, T. J., Albert, C. J., Suchy, F. J., Wang, D. Q. ‐., Ananthanarayanan, M., Ford, D. A., & Baldán, Á. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201228 · Cited by 159
Goedeke, L., Salerno, A., Ramírez, C. M., Guo, L., Allen, R. M., Yin, X., Langley, S. R., Esau, C., Wanschel, A., Fisher, E. A., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404046 · Cited by 145 · cited 1×
“These results are in contradiction to reports that have demonstrated that chronic anti-miR-33 therapy increases circulating TAG levels and hepatic lipid content [83, 85].”
ResultSelf-citationA Regulatory Role for MicroRNA 33* in Controlling Lipid Metabolism Gene Expression
Goedeke, L., Vales-Lara, F. M., Fenstermaker, M., Cirera-Salinas, D., Chamorro-Jorganes, A., Ramírez, C. M., Mattison, J. A., de Cabo, R., Suárez, Y., & Fernández-Hernando, C. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01714-12 · Cited by 140
Self-citationGenetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis
Price, N. L., Rotllan, N., Canfrán-Duque, A., Zhang, X., Pati, P., Arias, N., Moen, J., Mayr, M., Ford, D. A., Baldán, Á., et al. (2017) · Cell reports · doi:10.1016/j.celrep.2017.10.023 · Cited by 129 · cited 10×
“These findings correlate with a recent study published from our group demonstrating that genetic ablation of miR-33 in hematopoietic cells protects against the progression of atherosclerosis without altering plasma HDL-C levels [68].”
BackgroundResultSelf-citationRottiers, V., Obad, S., Petri, A., McGarrah, R., Lindholm, M. W., Black, J. C., Sinha, S., Goody, R. J., Lawrence, M. S., deLemos, A. S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006840 · Cited by 121
Marquart, T. J., Wu, J., Lusis, A. J., & Baldán, Á. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300639 · Cited by 110 · cited 1×
“However, other studies with miR-33 inhibitors have not observed any differences in circulating HDL-C levels or atherosclerotic plaque development [65].”
ResultThe RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation
Mobin, M. B., Gerstberger, S., Teupser, D., Campana, B., Charisse, K., Heim, M. H., Manoharan, M., Tuschl, T., & Stoffel, M. (2016) · Nature Communications · doi:10.1038/ncomms12848 · Cited by 55
miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages
Vinod, M., Chennamsetty, I., Colin, S., Belloy, L., De Paoli, F., Schaider, H., Graier, W. F., Frank, S., Kratky, D., Staels, B., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.02.006 · Cited by 44
Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33
Allen, R. M., Marquart, T. J., Jesse, J. J., & Baldán, Á. (2014) · Circulation Research · doi:10.1161/circresaha.115.303100 · Cited by 38
Cited by
Interleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4
Wang, C., Chen, Z., Yi, Y., Ding, Y., Xu, F., Kang, H., Lin, K., Shu, X., Zhong, Z., Zhang, Z., et al. (2024) · Oncogene · doi:10.1038/s41388-023-02902-4 · Cited by 42
MicroRNA-33 Inhibits Adaptive Thermogenesis and Adipose Tissue Beiging
Afonso, M. S., Verma, N., van Solingen, C., Cyr, Y., Sharma, M., Perie, L., Corr, E. M., Schlegel, M., Shanley, L. C., Peled, D., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315798 · Cited by 21
Potential Therapeutic Targeting of lncRNAs in Cholesterol Homeostasis
Ye, W.-C., Huang, S.-F., Hou, L.-J., Long, H.-J., Yin, K., Hu, C. Y., & Zhao, G.-J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.688546 · Cited by 19
Metadata
- Authors
- Singh, A. K., Aryal, B., Zhang, X., Fan, Y., Price, N. L., Suárez, Y., & Fernández-Hernando, C.
- Venue
- Seminars in Cell & Developmental Biology
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 81
- Pages
- 129-140
- ISSN
- 1084-9521 (ISSN-L)
- OpenAlex
- W2772479564
- Cited by
- 54
- References
- 39
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.